Skrepnek, Grant H <br/><br/>
Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.  [electronic resource] 

 -  Pharmacotherapy  Mar 2005 
 - 325-34 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0277-0008 
<br/><br/><label>Standard No.: </label>10.1592/phco.25.3.325.61593  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents--economics<br/>Benzamides<br/>Bone Marrow Transplantation--economics<br/>Chronic Disease<br/>Cost-Benefit Analysis<br/>Decision Support Techniques<br/>Health Care Costs<br/>Humans<br/>Imatinib Mesylate<br/>Insurance, Health, Reimbursement--economics<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--economics<br/>Male<br/>Markov Chains<br/>Monte Carlo Method<br/>Piperazines--economics<br/>Pyrimidines--economics